Custom Cancer Stem Cells
TGN can provide CSC-amplified or purified (up to 10 million CSCs) tumoroids for use in drug discovery, basic/translational research and assessing clinical drug efficacy.
Our FiSSCSC technology has several advantages:
FiSS produces ~10-fold increase in the CSC population vs monolayer cells
FiSS amplification of CSCs can be easily scaled up by using 6-well plates
CSC-enriched cells can be stored frozen without affecting the viability of CSCs
CSCs can be amplifed from patient biopsies and tumor cells
FiSS discs enable CSC production for drug discovery and biomarker studies
CSC investigations are typically limited by low abundance of CSCs in vivo (≤ 1%) and the phenotypic plasticity they exhibit during expansion.